Search results
Showing 1441 to 1455 of 1834 results for carers
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711
Discontinued Reference number: GID-TA10133
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)
Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).
Digital self-help for eating disorders: early value assessment (HTG768)
Early value assessment (EVA) guidance on digital self-help for eating disorders.
This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.
View quality statements for QS9Show all sections
Sections for QS9
- Quality statements
- Quality statement 1: N-terminal pro-B-type natriuretic peptide measurement
- Quality statement 2: Specialist assessment
- Quality statement 3: Medication for newly diagnosed and pre-existing chronic heart failure with reduced ejection fraction
- Quality statement 4: Review after changes in medication
- Quality statement 5: Review of people with chronic heart failure
- Quality statement 6: Cardiac rehabilitation
- Update information
This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS166Show all sections
Sections for QS166
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)
Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.
Evidence-based recommendations on loncastuximab tesirine (Zynlonta) for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments.
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Discontinued Reference number: GID-TA10277
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
Discontinued Reference number: GID-TAG393
Optical Coherence Tomography to guide percutaneous coronary intervention
In development Reference number: GID-IPG10394 Expected publication date: TBC
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued Reference number: GID-TA10105